TransCode Therapeutics, Inc.’s Post

The Future of Exosome Based Therapeutics: Key Clinical Updates ZEO ScientifiX™ invites you to a LIVE Webinar on The Future of Exosome Based Therapeutics with Dr. George Shapiro, MD https://lnkd.in/g5pnyr42

With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers

Come join us on April 17th at 9am at the Colonnade Hotel in Boston, MA at the 4th Fc Mediated Function Summit and learn about how to incorporate our platform in order to develop safer more efficacious monoclonal therapeutics. #mAbtherapeutics #Fceffectorfuntion #Fcmediatedfunctionsummit

Harness the power of OncolinesProfiler’s™ sophisticated clustering analysis to map your compound’s IC50 fingerprint against the cellular activity of 213 anti-cancer therapeutics. Gain deep insights into your drug's biochemical action. Check out our capabilities and learn what we can do for you. https://ow.ly/X40x50QkHo2 #bioinformatics #comparativeprofiling

It's not too late to attend this webinar today - Pharmacogenomics: Transforming Patient Care

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials

Check out this Perspective article from Bioanalysis, which describes four case studies illustrating the challenges and considerations of different methodologies for the bioanalysis of oligonucleotide therapeutics >>> https://hubs.ly/Q02QKCQN0

Last night's CAR T Cell Therapy webinar had over 1,400 registrants and generated over 115 questions in the Q&A. THANK YOU to the lupus community for showing up and to our supportive sponsors who didn't think twice about helping to make this possible when I called and asked for help!! This tells me we need to do more to educate the lupus community on this and other research-related topics, so stay tuned for what's next! #patientadvocacy #lupusresearch #immunology #nephrology #carcelltherapy #cartcelltherapy #lupus #lupusnephritis #researchwebinar

$MDNAF $MDNA.to We expect to provide a comprehensive data-set on monotherapy from MDNA11 dose-expansion trial And some topline data on combo trial with #Ketruda Finally Sachs shared another great presentation by Dr. Fahar, MDNA's CEO at the 10th Annual Oncology Innovation Forum!

Back-to-back development candidates progressing into the clinic is no mean feat! Following on the footsteps of VYN201 which progressed into Phase 2b last month; this week we are delighted to share that dosing of the first participants in the Phase 1a trial of VYN202 has taken place. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. VYN202 was discovered by the team at Tay Therapeutics before being licensed to VYNE Therapeutics who are leading clinical development. Top-line data is expected in the second half of 2024. https://lnkd.in/ePG4eb7V https://lnkd.in/eGtRw7Ty